Volume 12, Number 11—November 2006
Research
Staphylococcus aureus–associated Skin and Soft Tissue Infections in Ambulatory Care
Table 4
Therapeutic subclass† | 1992–1994 | 2001–2003 | ||
---|---|---|---|---|
No. prescriptions/10,000 visits/y | 95% CI | No. prescriptions/10,000 visits/y | 95% CI | |
All visits | 6,899.9 | 6431.5–7368.3 | 7,298.6 | 6870.7–7726.5 |
Cephalosporins | 3,039.3 | 2,704.5–3374.1‡ | 3,558.3 | 3,191.2–3,925.4‡ |
Penicillins | 1,098.7 | 826.1–1371.3 | 1,404.2 | 1,141.0–1,667.4 |
Lincosamides and macrolides | 1,377.7 | 1,081.9–1673.5 | 668.7 | 508.6–828.8 |
Quinolones | § | NA | 646.3 | 472.8–819.8 |
Sulfonamides and related compounds, antibacterial agents, miscellaneous | 580.8 | 390.9–770.7 | 542.2 | 361.9–722.5 |
Tetracyclines | 134.2 | 73.6–194.8 | 258.3 | 146.8–369.8
*CI, confidence interval; NA, not applicable. |
*CI, confidence interval; NA, not applicable.
†Therapeutic subclass is based on the standard 4-digit drug classification used in the National Drug Code Directory, 1985 and 1995 editions, respectively.
‡1992–1994 95% CI overlaps with 2001–2003 95% CI, but p<0.05.
§Does not meet standard of reliability or precision.
Page created: October 14, 2011
Page updated: October 14, 2011
Page reviewed: October 14, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.